Jan 19, 2021 (Baystreet.ca via COMTEX) -- One under-the-radar company looks to be an absolute game-changer for the healthcare industry.
That’s because, despite “Big Pharma’s” massive resources and staggering amounts of spending, no large pharmaceutical company has ever been able to solve the industry’s most critical problem.
That problem is a woefully inefficient drug development process.
Drug development for major pharmaceutical companies can take as long as a decade...and cost hundreds of billions of dollars in research and development.
Yet a small, little-known company – which could become a truly disruptive cannabis player – now appears uniquely positioned to upend the drug development market by developing evidence-based cannabis products to combat many of the world’s most serious medical conditions.
Juva Life /zigman2/quotes/222626576/delayed CA:JUVA +5.00% /zigman2/quotes/222111944/composite JUVAF +3.60% is a California-based life science company – with roots in the cannabis industry, that is aiming at outsized profit potential by working to unlock the boundless therapeutic value of cannabis.
By potentially solving the massive problem that Big Pharma doesn’t like to admit, this small company offers the chance for true “market disruption” in this aspect of healthcare.
This company’s story is truly amazing: Juva Life is a small, research-based company – led by a team of cannabis pioneers – that is working hard to do what Big Pharma can’t.
They’re aiming to create targeted health solutions much faster – and much cheaper – than large pharmaceutical companies are capable of... by following a strict, science-based approach.
And while the company is a relative unknown at the moment, the nature of their work means that a great deal of attention could soon be headed their way.
Cannabis Revenues Support Potentially Massive, Research-Based Therapeutics Development
Before examining the high upside potential of Juva Life’s natural product therapies, it’s important to understand that the company’s work in this area is built on a solid foundation of vertical integration.
That’s because Juva Life essentially consists of two businesses that support each other in a way that allows for significant potential upside.
The first business is the company’s cannabis business – a vertically integrated cannabis operation located in northern California. Their cannabis business includes manufacturing, cultivation, distribution, and delivery capabilities, allowing it to take advantage of the massive California cannabis market.
We’ll examine their cannabis business in greater detail in just a moment. For now, keep in mind this important fact: Their cannabis business can create the infrastructure and revenue to support the company’s potentially far more lucrative research therapeutics division.
The current healthcare model is simply not working for millions of people.
Optimal health solutions simply aren’t available in many cases because of our slow drug development process.
In order to develop a pharmaceutical-based drug – one that can be prescribed by a doctor – a company must be ready to invest up to 10 years of research and development along with potentially hundreds of millions of dollars.
We now know that this is a woefully inefficient model, which is why they are working to offer a potentially faster process for cannabis-based alternatives.
Juva Life is building a novel technology platform founded on a more efficient clinical development pathway.
This science-based approach offers a potentially game-changing alternative to what Big Pharma is currently offering the market. They are working to develop effective, targeted health solutions -- based on hard scientific evidence -- much more rapidly and at far less cost than Big Pharma is currently capable of.
To date, there has been limited working knowledge and standard practice in the pharmacology of cannabis...but Juva Life is working quickly to change that in a significant way.
Addressing the Increasing Demand for Evidence-Based, Natural Product Therapies
There’s no question that both consumers and investors are aware of the role that cannabis can play in helping to improve people’s health.
In addition, many states – along with the federal government – are in the process of easing regulations on cannabis.
This increase in awareness, combined with easing regulations, means that demand is increasing for evidence-based cannabis products that address serious medical conditions.
The company is led by a team of cannabis industry pioneers and scientists – including Doug Chloupek, the recipient of the very first permit ever issued in the state of California – with expertise in the science of cannabis for product development.
Rather than pursue FDA approvals that could take up to ten years, their therapeutics division is involved in medicinal cannabis-based product research that is designed to be far more efficient.
Using IRB-approved patient research registries and their collection of real-world data with patient-reported and clinical outcomes, their research division will work to develop a wide range of pharmacy-grade cannabis products.
These products will each be rigorously tested, and meticulously formulated.
Perhaps best of all, this efficient clinical development pathway – with a laser-like focus on consumer needs – are aimed to help the company develop these products much more quickly than traditional drug development with far less risk and at significantly less cost.
This type of product development should also – for the first time – allow consumers to take the guesswork out of medical cannabis and get the right solution for their specific medical condition.
It’s a truly scientific approach – one that can be licensed to drug developers to help accelerate their research trials.
Juva Life’s Research-Based Tech Platform Offers Valuable Potential for Big Pharma
If successful, Juva Life’s research-based technology platform for drug development could be an absolute game-changer – but it offers even greater potential than simply offering products directly to consumers.
The company’s tech platform, as well as its ever-growing database of information on specific efficacies of medical cannabis – would then be likely to attract significant attention from “Big Pharma.”
The reason is simple:
One of Big Pharma’s biggest problems is the mountains of money it costs and the time it takes to get new pharmaceutical drugs approved.
Juva Life’s /zigman2/quotes/222626576/delayed CA:JUVA +5.00% /zigman2/quotes/222111944/composite JUVAF +3.60% research protocols, already approved by the Western Institutional Review Board, could speed up the process dramatically.
And the company is compiling massive amounts of data, including statistically relevant information about how specific products and cannabis strains demonstrate efficacy when treating specific ailments.
That type of information “bank” could prove to be exceptionally valuable to large drug manufacturers.
At this moment, they appear to be a company with a valuable database on medical cannabis as well as a research-based tech platform for more rapid product development.
Those are the types of things that when successful make a company an especially attractive acquisition target as Big Pharma looks to shorten its drug development times and build a base of knowledge about the effectiveness of natural solutions.
Juva Life’s Cannabis Operations Offer Short-Term Revenue Opportunities
As a vertically integrated company, they pursue four revenue streams. We’ve already examined the company’s potential in the area of medical research.
In addition to their research, Juva Life’s manufacturing, delivery, and retail revenue streams provide significant upside potential that helps fund the company’s medical research efforts.
Think of it as a vertically integrated cannabis business – with estimated production capabilities of 865 pounds of cannabis flower per month – PLUS a high potential life science business that could attract significant acquisition attention from Big Pharma.
In terms of the cannabis revenue streams, they have...
1. Manufacturing – Juva Manufacturing will create Juva Life’s in-house brands as well as white label products for other licensed recreational and medical cannabis companies.
2. Delivery – Juva Delivery is a network of cannabis delivery companies that service the San Francisco Bay Area and other cities within the state of California and currently generates at a run rate of $2.5 million in annual revenue for the company. Juva Delivery offers a broad array of the best, most trusted, lab-tested products – from flower, pre-rolls, and health-conscious edibles to tinctures, creams, transdermal patches, and much more.